A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial ...

In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or ...

Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Weight loss drugs are getting more popular, even for teenagers and pre-teens -- but while many doctors have reported ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial ...

MALAGA, Spain—Patients with obesity treated with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy; Novo Nordisk) can achieve weight loss in the real world similar to what has ...

In 2022, for example, Dr. Aronne led a study showing that a 72-week course of tirzepatide at its maximum dosage reduced body weight by 20.9%; a similar study published in 2021 reported a 14.9% ...